Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data.

Saved in:
Bibliographic Details
Title: Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data.
Authors: Schelter BO; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK., Shiells H; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Lo S; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK., Nazlee N; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Evans E; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Bentham P; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK., Gauthier S; Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom; UK Dementia Research Institute at UCL, London, United Kingdom; Hong Kong Centre for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China; Wisconsin Alzheimer's Disease Research Centre, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison WI 53792, USA., Wilcock GK; Geratology, University of Oxford, Oxford, UK., Froelich L; Department of Geriatric Psychiatry, Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Mannheim (SCU-B), Germany., Burns A; University of Manchester, Manchester, UK., MacSweeney E; Re:Cognition Health London UK., Ballard C; Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK., Yu JT; Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China., Choon TS; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Asvatourian V; Cytel Inc. 675 Massachusetts Ave, Cambridge, MA 02139, USA., Muehlemann N; Cytel Inc. 675 Massachusetts Ave, Cambridge, MA 02139, USA., Priel J; Cytel Inc. 675 Massachusetts Ave, Cambridge, MA 02139, USA., Kook K; Salamandra LLC, Bethesda, MD, USA., Sullivan T; Salamandra LLC, Bethesda, MD, USA., Downie D; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Miller S; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Pringle C; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Storey JMD; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, UK., Baddeley T; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, UK., Harrington CR; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK., Staff R; Aberdeen Royal Infirmary NHS Grampian, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK., Sandu AL; Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Lilian Sutton Building, Foresterhill, Aberdeen AB25 2ZD, UK., Hull C; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK., Stefanacci R; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Thomas Jefferson University, Philadelphia, PA, USA., Wischik CM; TauRx Therapeutics Ltd., Aberdeen AB24 5RP, UK; Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK. Electronic address: cmw@taurx.com.
Corporate Authors: Alzheimer's Disease Neuroimaging Initiative
Source: The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2026 Jun; Vol. 13 (6), pp. 100560. Date of Electronic Publication: 2026 Apr 17.
Publication Type: Journal Article
Journal Info: Publisher: Springer International Publishing Country of Publication: United States NLM ID: 101638820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2426-0266
DOI:10.1016/j.tjpad.2026.100560